HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced <i>EGFR</i> -mutated NSCLC after a third-generation EGFR TKI
Tony Mok, Pasi A. Jänne, Makoto Nishio, Silvia Novello, Martin Reck, Conor Steuer, Yi‐Long Wu, Ronan Fougeray, Pang‐Dian Fan, Jie Meng, David Sternberg, Stephen Esker, Helena A. Yu
Abstract
After disease progression on EGFR tyrosine kinase inhibitor (TKI) therapy, patients with EGFR-mutated NSCLC who are then treated with platinum-based chemotherapy (PBC) obtain only limited clinical benefit with transient responses. Therapies with greater efficacy and tolerable safety profiles are needed in this setting. The receptor tyrosine kinase HER3 is widely expressed in NSCLC, and increased expression is associated with poor treatment outcomes. In the U31402-A-U102 phase I trial, HER3-DXd showed promising antitumor activity with manageable safety in heavily pre-treated patients with EGFR-mutated NSCLC across a range of tumor HER3 expression levels and EGFR TKI resistance mechanisms. HERTHENA-Lung02 is the first phase III trial to evaluate the safety and efficacy of HER3-DXd versus PBC in patients with progression on a third-generation EGFR TKI. Clinical Trial Registration: NCT05338970 (clinicaltrials.gov); 2021-005879-40 (EudraCT Number).